Retinol-binding Protein 4 (RBP4) Metabolizm in Type 2 Diabetes Progression and Associated Cardiovascular Complications

Study Overview
=================
Brief Summary
-----------------
Retinol-binding protein 4 (RBP4) may affects obesity development and the development of obesity-related diseases including insulin resistance, type 2 diabetes, steatohepatitis and cardiovascular disease. This study aims to examine the involvement of RBP4 in patients with diagnosed diabetes, diabetic cardiovascular disease, pre-diabetes (pre-DM) and healthy controls during the progression of T2DM, and to evaluate the ability of RBP4 to predict cases of diabetes with an elevated risk of cardiovascular complications . Along with animal experiment.

Detailed Description
-----------------
A total of 500 Chinese patients admitted to the First Affliated Hospital of Xi'an Jiaotong University (Xi'an, China) between March 2020 and March 2022 were recruited to investigate the RBP4 profles. Peripheral blood samples are drawn at the initial medical examination, in the morning after a fast of at least 8 h, and immediately stored at -80˚C until the sphingolipid measurements were performed. Blood pressure, WC, hip circumference (HC), body weight and body height were measured by a trained physician. The participants enrolled in the study provided written informed consent.

Official Title
-----------------
Retinol-binding Protein 4 (RBP4) Metabolizm in Type 2 Diabetes Progression and Associated Cardiovascular Complications

Conditions
-----------------
Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Other: Exposure factors


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: T2DM: Fasting plasma glucose (FPG)≥7.0 mmol/l; 2 h plasma glucose (2hPG) ≥11.1 mmol/l; glycated hemoglobin (HbA1c) level ≥6.5%; random plasma glucose ≥11.1 mmol/l plus symptoms of hyperglycemia; T2DM diagnosed previously. Pre-DM was defned as follows: FPG ≥5.6-6.9 mmol/l 2hPG 7.8-11.0 mmol/l HbA1c 5.7-6.4%. Exclusion Criteria: type 1 diabetes liver or kidney disorders.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| RBP4 in diabetes<br>RBP4 in diagnosed diabetes. | Other: Exposure factors<br>* Exposure factors，such as diet，exercise，environment<br>|
| RBP4 in pre-diabetes (pre-DM)<br>RBP4 in pre-diabetes (pre-DM). | Other: Exposure factors<br>* Exposure factors，such as diet，exercise，environment<br>|
| RBP4 in DM-CVD<br>RBP4 in diabetic cardiovascular disease. | Other: Exposure factors<br>* Exposure factors，such as diet，exercise，environment<br>|
| RBP4 in CVD<br>RBP4 in single coronary artery disease. | Other: Exposure factors<br>* Exposure factors，such as diet，exercise，environment<br>|
| RBP4 in NC<br>RBP4 in healthy controls. | Other: Exposure factors<br>* Exposure factors，such as diet，exercise，environment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum RBP4 level | serum RBP4 level in DM, pre-DM, CVD, DM-CVD and healthy controls. | 2022.3 |